STOCK TITAN

WORK Medical Technology Group LTD (WOK) Financials

WOK
FY2025 annual
Revenue $9.8M -14.4% YoY
Net Income -$1.1M +69.3% YoY
EPS (Diluted) -$0.04 YoY not available
Free Cash Flow $4.9M +142.9% YoY
Market Cap $6.0M as of Oct 14, 2026
Price / Sales 0.6x on $9.8M revenue, FY2025
Price / Earnings n/m net loss, so no earnings multiple, FY2025
Price / Book 0.3x on $18.3M equity, Q4 FY2025

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 14, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period FY2025, ended Sep 30, 2025 Reported Currency USD FYE September

Newest figures come from the 20-F for FY2025, filed Jan 30, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the WOK SEC filings page.

WORK Medical Technology Group LTD (WOK) reported $9.8M in revenue for fiscal year 2025, down 14.4% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI WOK FY2025

Cash generation recovered despite continued losses, but shrinking sales and narrowing gross margins show the business remains under operating pressure.

FY2025 free cash flow of $4.9M contrasted with a net loss of $1.1M because receivables and inventory declined while capital spending fell sharply. That makes the cash improvement look driven partly by working-capital release and reduced reinvestment, rather than by stronger underlying profitability.

Revenue declined from $13.6M in FY2023 to $9.8M in FY2025, while gross margin compressed from 30.5% to 23.8%. The combination points to weaker scale and less gross profit available to absorb operating costs, even after selling and administrative spending was reduced.

The balance sheet became less burdened by liabilities: the reported debt-to-equity ratio fell from 1.5x in FY2024 to 0.7x in FY2025, while the current ratio improved from 1.0x to 1.7x. This gives the company more short-term balance-sheet flexibility, but the FY2025 net margin remained negative at -10.9%.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Profitability Growth Leverage Liquidity CashFlow Returns 22 / 100
Financial Health Score 22/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of WORK Medical Technology Group LTD's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability
0

Not available for WORK Medical Technology Group LTD, and counted as zero in the overall score.

Growth
6

WORK Medical Technology Group LTD's revenue declined 14.4% year-over-year, from $11.5M to $9.8M. This contraction results in a growth score of 6/100.

Leverage
55

WORK Medical Technology Group LTD has a moderate D/E ratio of 0.65. This balance of debt and equity financing earns a leverage score of 55/100.

Liquidity
50

WORK Medical Technology Group LTD's current ratio of 1.71 indicates adequate short-term liquidity, earning a score of 50/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow
20

WORK Medical Technology Group LTD's free cash flow margin of 49.9% results in a low score of 20/100. Capital expenditures of $1.3M absorb a large share of operating cash flow.

Returns
0

Not available for WORK Medical Technology Group LTD, and counted as zero in the overall score.

Piotroski F-Score Partial
4/7

WORK Medical Technology Group LTD passes 4 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 3 of 4 profitability signals pass, all 1 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Mixed
N/A

WORK Medical Technology Group LTD reported a net loss of $1.1M while generating $6.2M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

None of these metrics is reported for Q4 2025.

Cash & Balance Sheet

Cash & Debt
$4.1M
YoY-37.7%
QoQ+104.9%

WORK Medical Technology Group LTD held $4.1M in cash as of Q4 2025; long-term debt is not reported for that period.

Free Cash Flow

Not reported for Q4 2025.

Dividends Per Share

Not reported for Q4 2025.

Shares Outstanding

Not reported for Q4 2025.

Margins & Returns

None of these metrics is reported for Q4 2025.

Capital Allocation

None of these metrics is reported for Q4 2025.

WOK Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

WOK quarterly income statement
MetricQ4'2520-FQ2'2510-QQ4'2420-FQ4'2310-K

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, Net Income, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).

WOK Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

WOK quarterly balance sheet
MetricQ4'2520-FQ2'2510-QQ4'2420-FQ4'2310-K
Total Assets$33.2M-8.5%$34.7M$36.3M+21.0%$30.0M
Current Assets$20.5M-1.8%$21.6M$20.8M-6.0%$22.2M
Cash & Equivalents$4.1M-37.7%$2.0M$6.6M+310.9%$1.6M
Short-Term Investments$0$0$0$0
Inventory$2.5M-22.9%$3.0M$3.2M-31.1%$4.6M
Accounts Receivable$616K-62.6%$877K$1.6M-50.5%$3.3M
Long-Term Investments$0$0$0$0
Total Liabilities$12.0M-40.6%$19.0M$20.2M+6.4%$19.0M
Current Liabilities$12.0M-40.7%$19.0M$20.2M+6.6%$18.9M
Non-Current Liabilities$20K$17K$0-100.0%$50K
Total Equity$18.3M+39.1%$12.9M$13.2M+33.5%$9.9M
Retained Earnings$5.0M-18.4%$6.1M$6.1M-36.6%$9.6M

Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.

WOK Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

WOK quarterly cash flow statement
MetricQ4'2520-FQ2'2510-QQ4'2420-FQ4'2310-K

Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.

WOK Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

WOK quarterly financial ratios
MetricQ4'2520-FQ2'2510-QQ4'2420-FQ4'2310-K
Current Ratio1.71+0.7x1.141.03-0.1x1.17
Debt-to-Equity0.65-0.9x1.471.53-0.4x1.92

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company Fiscal year Revenue Net income Net margin Market cap Health score
WORK Medical Technology Group LTD WOK FY2025 $9.8M -$1.1M -10.9% $6.0M 22/100
Sensus Healthcare, Inc SRTS FY2025 $27.5M -$7.7M -28.1% $48.2M 48/100
Cytosorbents Corp. CTSO FY2025 $37.1M -$8.2M -22.1% $11.3M 37/100
Elutia Inc. ELUT FY2025 $12.3M $53.4M N/A $34.9M 26/100
Spectral AI, Inc. MDAI FY2025 $19.6M -$7.6M -38.5% $51.5M 37/100
Apyx Medical Corporation APYX FY2025 $52.8M -$11.2M -21.2% $111.6M 43/100

Frequently Asked Questions

What is WORK Medical Technology Group LTD's annual revenue?

WORK Medical Technology Group LTD (WOK) reported $9.8M in total revenue for fiscal year 2025. This represents a -14.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is WORK Medical Technology Group LTD's revenue growing?

WORK Medical Technology Group LTD (WOK) revenue declined by 14.4% year-over-year, from $11.5M to $9.8M in fiscal year 2025.

Is WORK Medical Technology Group LTD profitable?

No, WORK Medical Technology Group LTD (WOK) reported a net income of -$1.1M in fiscal year 2025, with a net profit margin of -10.9%.

WORK Medical Technology Group LTD (WOK) reported diluted earnings per share of -$0.04 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

WORK Medical Technology Group LTD (WOK) had a gross margin of 23.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

WORK Medical Technology Group LTD (WOK) had a net profit margin of -10.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

WORK Medical Technology Group LTD (WOK) has a return on equity of -5.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

WORK Medical Technology Group LTD (WOK) generated $4.9M in free cash flow during fiscal year 2025. This represents a 142.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

WORK Medical Technology Group LTD (WOK) generated $6.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

WORK Medical Technology Group LTD (WOK) had $33.2M in total assets as of fiscal year 2025, including both current and long-term assets.

WORK Medical Technology Group LTD (WOK) invested $1.3M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

WORK Medical Technology Group LTD (WOK) invested $435K in research and development during fiscal year 2025.

WORK Medical Technology Group LTD (WOK) had a current ratio of 1.71 as of fiscal year 2025, which is generally considered healthy.

WORK Medical Technology Group LTD (WOK) had a debt-to-equity ratio of 0.65 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

WORK Medical Technology Group LTD (WOK) had a return on assets of -3.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

WORK Medical Technology Group LTD (WOK) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $6.0M as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

WORK Medical Technology Group LTD (WOK) trades at 0.6x sales, its market capitalization divided by revenue of $9.8M revenue, FY2025. The market capitalization is $6.0M as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

WORK Medical Technology Group LTD (WOK) has a Piotroski F-Score of 4 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

WORK Medical Technology Group LTD (WOK) reported a net loss of $1.1M while generating $6.2M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

WORK Medical Technology Group LTD (WOK) scores 22 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top